Gepotidacin: A First-in-Class Bacterial Type II Topoisomerase Inhibitor

Executive Summary: Gepotidacin (GSK2140944, SKU BA1220) is a triazaacenaphthylene antibacterial agent that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting bacterial DNA replication and supercoiling (see Lancet 2025). It exhibits low micromolar to submicromolar IC50 values against key bacterial enzymes, including activity against fluoroquinolone-resistant strains (APExBIO). Phase 3 clinical data show non-inferiority to standard-of-care in treating uncomplicated urogenital gonorrhea, with microbiological success rates exceeding 92% (Lancet 2025). Gepotidacin is supplied as a solid (MW 448.52, formula C24H28N6O3), is stable at -20°C, and is intended for research use only (APExBIO).

Biological Rationale

Bacterial DNA replication is essential for cell viability. Type II topoisomerases, including DNA gyrase and topoisomerase IV, control DNA supercoiling and untangling during replication (Lancet 2025). Many resistant pathogens exploit mutations in these enzymes to escape classic antibiotics. Gepotidacin targets a unique binding site on these enzymes, bypassing common mechanisms of resistance (APExBIO). This approach is critical for addressing multidrug-resistant Gram-positive and Gram-negative pathogens, including Neisseria gonorrhoeae, MRSA, and E. coli. Gepotidacin’s distinct mechanism supports its use in antibacterial research and next-generation antibiotic development, complementing and extending findings in previous literature (see this article for a translational research roadmap).

Mechanism of Action of Gepotidacin

Gepotidacin is a triazaacenaphthylene compound that binds to bacterial DNA gyrase and topoisomerase IV at a site distinct from fluoroquinolones. This binding induces single-stranded DNA breaks during the supercoiling and relaxation steps of DNA replication (Lancet 2025). Gepotidacin inhibits S. aureus gyrase-mediated DNA negative supercoiling with an IC50 of ~0.047 μM and blocks relaxation of positive supercoils at ~0.6 μM. It induces single-stranded DNA breaks with EC50 values of 0.13 μM (negatively supercoiled DNA) and 0.18 μM (positively supercoiled DNA) (APExBIO). By disrupting DNA topology, it effectively halts bacterial cell division and growth. This unique pathway sets Gepotidacin apart from other bacterial topoisomerase inhibitors, as discussed in greater detail in this review, which Gepotidacin's clinical benchmarks now update.

Evidence & Benchmarks

• Gepotidacin demonstrated a microbiological success rate of 92.6% (187/202) in phase 3 clinical trials for uncomplicated urogenital gonorrhea, non-inferior to ceftriaxone plus azithromycin (91.2%, 186/204) (Lancet 2025).
• MIC90 values: 0.5 μM for MRSA, 2 μM for E. coli, 0.5 μM for N. gonorrhoeae, and 0.25 μM for S. pyogenes, under standardized in vitro conditions (APExBIO).
• Effective dosing in vivo: 1500 mg orally twice daily for UTIs, and two 3000 mg oral doses 10–12 hours apart for gonorrhea, simulating human pharmacokinetics (Lancet 2025).
• IC50 for inhibition of S. aureus DNA gyrase: 0.047 μM (25°C, pH 7.4, standard buffer) (APExBIO).
• Active against fluoroquinolone-resistant strains, including multidrug-resistant N. gonorrhoeae and MRSA (Lancet 2025).
• Adverse events in clinical trials were mainly mild or moderate gastrointestinal symptoms; no severe or serious treatment-related events reported (Lancet 2025).

Applications, Limits & Misconceptions

Gepotidacin is a valuable tool for antibacterial activity testing against a broad spectrum of pathogens, including those resistant to fluoroquinolones. It supports research on bacterial topoisomerase pathways and informs novel antibiotic development. Gepotidacin is supplied by APExBIO strictly for scientific research, not for diagnostic or therapeutic use (product page).

For practical applications in research, see this workflow guide, which this article extends with updated clinical and molecular benchmarks.

Common Pitfalls or Misconceptions

• Not active against eukaryotic topoisomerases: Gepotidacin's selectivity is for bacterial enzymes; it does not affect mammalian topoisomerase II at research concentrations (APExBIO).
• Not suitable for long-term solution storage: Gepotidacin solutions degrade; use immediately after preparation (APExBIO).
• Not for clinical/diagnostic use: The compound is intended only for research, not patient treatment.
• Species-specific efficacy: MIC values vary; confirm activity in target organism under test conditions.
• Oral dosing in clinical studies should not be extrapolated to animal models without pharmacokinetic adjustment.

Workflow Integration & Parameters

Formulation & Storage: Gepotidacin is provided as a solid (MW 448.52, C24H28N6O3). Store at -20°C. Avoid long-term storage of solutions; prepare fresh for each experiment (APExBIO).

In Vitro Testing: Typical concentrations: 0.015–32 μM. Use standardized bacterial culture media and confirm pH and buffer compatibility. MIC and IC50 determinations should follow CLSI or EUCAST guidelines.

In Vivo Modeling: For translational studies, oral dosing regimens of 1500 mg BID (UTI) or 2 × 3000 mg (gonorrhea) have been shown to simulate human pharmacokinetics and efficacy (Lancet 2025). Adjust dosing for animal models based on allometric scaling.

Shipping: Product is shipped on Blue Ice for stability (APExBIO).

For broader context on mechanistic and translational research applications, see this mechanistic review, which this article updates with recent clinical validation.

Conclusion & Outlook

Gepotidacin, as a first-in-class triazaacenaphthylene bacterial type II topoisomerase inhibitor, addresses major challenges in antibiotic resistance research. Its validated efficacy against multidrug-resistant pathogens and favorable in vitro and in vivo benchmarks make it central to antibacterial research workflows. Ongoing and future research should explore its utility in combination regimens and resistance mechanism studies. For reagent details and ordering, see the Gepotidacin BA1220 product page at APExBIO.